Novartis International AG Says Osteoporosis Drug Approved in Europe

October 5, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

ZURICH, Oct 5 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX: Quote, Profile, Research) said on Friday its Aclasta drug had been approved by the European Commission for once-yearly treatment of women with post-menopausal osteoporosis.

Twitter
LinkedIn
Facebook
Email
Print

FDA Approvals Europe